MedTrace Logo

Safety, Tolerability and Pharmacokinetics of XW10508 Immediate and Modified Release Formulations in Healthy Adults

NCT04966832 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2022-11-04

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of XW10508 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

XW10508

XW10508 capsules or tablets

OTHER

Placebo

Placebo capsules or tablets

Sponsors & Collaborators

  • XWPharma

    lead INDUSTRY

Principal Investigators

  • Daniel M Canafax, PharmD · XWPharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-13
Primary Completion
2022-06-13
Completion
2022-06-13

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04966832 on ClinicalTrials.gov